<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606461</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-020</org_study_id>
    <secondary_id>2015-003594-14</secondary_id>
    <nct_id>NCT02606461</nct_id>
  </id_info>
  <brief_title>Selinexor in Advanced Liposarcoma</brief_title>
  <acronym>SEAL</acronym>
  <official_title>A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of
      patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 334
      total patients will be randomized to study treatment (selinexor or placebo).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Phase 2 portion of the study, 57 patients were randomized to selinexor (60 mg) or
      placebo at a 1:1 allocation ratio.

      In the Phase 3 portion of the study, approximately 277 patients will be randomized to
      selinexor (60 mg) or placebo with a 2:1 allocation ratio.

      Patients who progress during the blinded portion of the study will be unblinded and if
      receiving:

        -  placebo, may cross over to open-label selinexor (60mg twice weekly)

        -  selinexor, will be withdrawn from further treatment and followed for survival

      Study treatment will be given twice weekly on Day 1 and Day 3 during Weeks 1-6 of each
      six-week (42 day) cycle until disease progression or intolerability.

      Treatment will continue until one or more of the following occurs:

        -  Disease progression, as defined by RECIST v1.1 Response Criteria

        -  Clinical progression, as determined by the treating physician

        -  Unacceptable AEs or failure to tolerate study treatment

        -  Patient withdrawal

        -  Patient discontinuation due to non-compliance
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess and compare Progression-free Survival (PFS) of patients with advanced unresectable DDLS treated with selinexor (60 milligrams [mg]) or placebo.</measure>
    <time_frame>From the date of randomization until the first date of disease progression, per RECIST v1.1 Response Criteria, or death due to any cause; up to approximately 30 months.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>Dedifferentiated Liposarcoma</condition>
  <arm_group>
    <arm_group_label>Selinexor 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2: 57 patients were randomized to selinexor or placebo in a 1:1allocation.
Phase 3: Approximately 277 patients will be randomized to selinexor (~185 patients) or placebo (~92 patients) in a 2:1 allocation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase 2: Approximately 57 patients were randomized to selinexor or placebo in a 1:1 allocation.
Phase 3: Approximately 277 patients will be randomized to selinexor (~185 patients) or placebo (~92 patients) in a 2:1 allocation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Selinexor 60mg</description>
    <arm_group_label>Selinexor 60mg</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥12 years of age

          2. Body surface area (BSA) ≥ 1.2 m2

          3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
             DDLS requiring treatment

          4. Must have measurable disease per RECIST v1.1 Response Criteria

          5. Radiologic evidence of disease progression within 6 months prior to randomization. If
             the patient received other intervening therapy after documented disease progression,
             further disease progression must be documented after the completion of the intervening
             therapy

          6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
             exceed 5 prior lines)

          7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
             days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
             with all clinically significant therapy- related toxicities having resolved to less
             than or equal to Grade 1

        Exclusion Criteria:

          1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

          2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
             (HIV) infection.

          3. Known central nervous system metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kauffman, M.D., Ph.D.</last_name>
    <email>Mkauffman@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD</last_name>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Forscher, MD</last_name>
      <email>Charles.Forscher@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Charles Forscher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartosz Chmielowski, MD</last_name>
      <email>BChmielowski@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Bartosz Chmielowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sant Chawla, MD</last_name>
      <phone>310-552-9999</phone>
      <email>santchawla@sarcomaoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sant Chawla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Ganjoo, MD</last_name>
      <email>kganjoo@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen Ganjoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado-Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hari Deshpande, MD</last_name>
      <email>hari.deshpande@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Hari Deshpande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Attia, DO</last_name>
      <phone>904-953-7290</phone>
      <email>Attia.Steven@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Attia, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Agulnik, FRCPC, MD</last_name>
      <email>Mark.Agulnik@nm.org</email>
    </contact>
    <investigator>
      <last_name>Mark Agulnik, FRCPC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Meyer, MD</last_name>
      <phone>410-955-8893</phone>
      <email>cmeyer12@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Christian Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edwin Choy, MD, PhD</last_name>
      <phone>617-724-4000</phone>
      <email>echoy@partners.org</email>
    </contact>
    <investigator>
      <last_name>Edwin Choy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Hohos, RM</last_name>
      <phone>617-582-7162</phone>
      <email>mhohos@partners.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Wagner, MM, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Schuetze, MD</last_name>
      <email>scotschu@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Schuetze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Olsen</last_name>
      <phone>507-266-5027</phone>
      <email>okuno.scott@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Okuno, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Van Tine, MD, PhD</last_name>
      <phone>314-362-7997</phone>
      <email>bvantine@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Van Tine, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Schwartz, MD</last_name>
      <phone>646-317-6041</phone>
      <email>gks2123@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrinal Gounder Gounder, MD</last_name>
      <phone>646-888-4167</phone>
      <email>gounderm@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Mrinal Gounder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health Physicians Partners</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Philip, MD</last_name>
      <email>tphilip@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Tony Philip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Institute of Cancer</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Riedel, M.D.</last_name>
      <phone>919-681-1883</phone>
      <email>richard.riedel@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Colleen Piechocki, RN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Richard Riedel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Cancer Center, Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Chen, MD</last_name>
      <phone>614-685-9754</phone>
      <email>james.chen@OSUmc.edu</email>
    </contact>
    <investigator>
      <last_name>James Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Ryan, MD</last_name>
      <email>ryanc@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Ryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Hartner, MD</last_name>
      <email>Lee.Hartner@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Lee Hartner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Burgess, MD</last_name>
      <phone>412-692-4724</phone>
      <email>burgessma@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Melissa Burgess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Davis, MD</last_name>
      <email>elizabeth.j.davis@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neeta Somaiah, MD</last_name>
      <phone>713-563-5056</phone>
      <email>nsomaiah@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Neeta Somaiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Loggers, MD PhD</last_name>
      <email>eloggers@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Loggers, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lore Decoster, MD</last_name>
      <email>lore.decoster@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Lore Decoster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filomena Mazzeo, MD</last_name>
      <email>Filomena.Mazzeo@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Filomena Mazzeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lore Lapeire, MD</last_name>
      <email>lore.lapeire@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Lore Lapeire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Center - Alberta Health Services</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hatim Karachiwala, MD</last_name>
      <email>hatim.karachiwala@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Hatim Karachiwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garth Nicholas, MD</last_name>
      <email>gnicholas@toh.on.ca</email>
    </contact>
    <investigator>
      <last_name>Garth Nicholas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albiruni Razak, MD</last_name>
      <phone>1 (647) 970 9845</phone>
      <email>albiruni.razak@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Albiruni Razak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Alcindor, MD</last_name>
      <email>Thierry.alcindor@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Thierry Alcindor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux,</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Italiano, MD</last_name>
      <email>A.Italiano@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine Italiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oscar Lambret Center</name>
      <address>
        <city>Lille Cedex 307</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Penel, MD</last_name>
      <email>n-penel@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Penel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>96373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yve Blay, MD</last_name>
      <email>jean-yves.blay@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yve Blay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Timone University Hospital</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Duffaud, MD</last_name>
      <email>florence.duffaud@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Duffaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Régional du Cancer de Montpellier (ICM)</name>
      <address>
        <city>Montpellier</city>
        <zip>4298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Cupissol, MD</last_name>
      <email>dcupissol@valdorel.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Didier Cupissol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLCC Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06789</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esma Saada-Bouzid, MD</last_name>
      <email>Esma.SAADA-BOUZID@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Esma Saada-Bouzid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Piperno-Neumann, MD</last_name>
      <email>sophie.piperno-neumann@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Piperno-Neumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Chevreau, MD</last_name>
      <email>chevreau.christine@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Christine Chevreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Le Cesne, MD</last_name>
      <email>axel.lecesne@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Axel Le Cesne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Hospital Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Reichardt, MD</last_name>
      <email>peter.reichardt@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Peter Reichardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Technische Universitaet Dresden Med. Fakultaet Carl Gustav Carus Med. Klinik u. Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Richter, MD</last_name>
      <email>Stephan.richter@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Richter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center for Tumor Diseases, Univeristy Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Gröschel, MD</last_name>
      <email>stefan.groeschel@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Gröschel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Kasper, MD</last_name>
      <email>Bernd.Kasper@medma.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Bernd Kasper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie Klinikum rechts der Isar der TU Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Bogner, MD</last_name>
      <email>Christian.Bogner@mri.tum.de</email>
    </contact>
    <investigator>
      <last_name>Christian Bogner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Yakobson, MD</last_name>
      <email>Alexy@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Alexander Yakobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aviad Zick, MD</last_name>
      <email>aviadz@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Aviad Zick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alona Zer, MD</last_name>
      <email>alonaz@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Alona Zer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rony Weitzen, MD</last_name>
      <email>weitzen@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Rony Weitzen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofer Merimsky, MD</last_name>
      <email>oferm@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ofer Merimsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>7030000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnold Cyjon, MD</last_name>
      <phone>972-9-977-9713</phone>
      <email>a_cyjon@asaf.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Arnold Cyjon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Candiolo Cancer Institute</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Grignani, MD</last_name>
      <email>Giovanni.grignani@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Grignani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori, Milan</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <email>Silvia.Stacchiotti@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Oncologia Medica Oncology Department</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guiseppe Badalamenti, MD</last_name>
      <email>giuseppe.badalamenti@unipa.it</email>
    </contact>
    <investigator>
      <last_name>Guiseppe Badalamenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Viscenzi, MD</last_name>
      <email>b.vincenzi@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Bruno Viscenzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Germans Trias Pujol&quot; University Hospital</name>
      <address>
        <city>Badalona</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Estival Gonzalez, MD</last_name>
      <email>aestival@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Anna Estival Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d´hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Valverde, MD</last_name>
      <email>cmvalverde@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Claudia Valverde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Lopez-Pousa, MD</last_name>
      <email>alopezp@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Antonio Lopez-Pousa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital ICO Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Garcia del Muro, MD</last_name>
    </contact>
    <contact_backup>
      <email>garciadelmuro@iconcologia.net</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier Garcia del Muro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Casado Herráez, MD</last_name>
    </contact>
    <contact_backup>
      <email>antoniocasado@telefonica.net</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Casado Herráez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Martin-Broto, MD</last_name>
      <email>jmartin@mustbesevilla.org</email>
    </contact>
    <investigator>
      <last_name>Javier Martin-Broto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Diaz Beveridge, MD</last_name>
      <email>rdiazbev@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Roberto Diaz Beveridge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Hansson, MD</last_name>
      <email>lina.hansson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Lina Hansson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Eriksson, MD</last_name>
      <email>Mikael.eriksson@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Mikael Eriksson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologiska Kliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antroula Papakonstantinou, MD</last_name>
      <email>antroula.papakonstantinou@sll.se</email>
    </contact>
    <investigator>
      <last_name>Antroula Papakonstantinou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Hatcher, MD</last_name>
      <email>kim.mcshane@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Helen Hatcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vasilios Karavasilis, MD</last_name>
      <email>vasilios.karavasilis@uclh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Vasilios Karavasilis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Jones, MD</last_name>
      <email>robin.jones@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Robin Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Leahy, MD</last_name>
      <email>Michael.leahy@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Michael Leahy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced unresectable dedifferentiated liposarcoma</keyword>
  <keyword>selinexor</keyword>
  <keyword>KCP-330</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>Phase 2 / 3</keyword>
  <keyword>dedifferentiated liposarcoma</keyword>
  <keyword>Liposarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

